Study Identifies MS Patients at Risk of Severe Disease Reactivation After Gilenya Is Discontinued
Fingolimod withdrawal may trigger the return of pretreatment disease activity. It is difficult to identify patients at risk of disease reactivation. We compared the demographic and clinical features of patients experiencing severe disease reactivation (SDR) after fingolimod cessation with those of patients who did not.
https://insights.ovid.com/crossref?a...01801000-00003
Fingolimod withdrawal may trigger the return of pretreatment disease activity. It is difficult to identify patients at risk of disease reactivation. We compared the demographic and clinical features of patients experiencing severe disease reactivation (SDR) after fingolimod cessation with those of patients who did not.
https://insights.ovid.com/crossref?a...01801000-00003
Comment